Issue Date: May 29, 2006
Antibody R&D deals abound
Schering-Plough has teamed up with antibody company Xoma, which will use its phage-display libraries and optimization technologies to discover antibody drugs against targets chosen by Schering-Plough. Xoma will conduct preclinical studies to support regulatory filings and is responsible for cell line and process development, as well as manufacture of antibodies for initial trials. In a separate deal, Icos has licensed Dyax's phage-display library for use in discovery and development of therapeutic . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society